Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610280 · ClinicalTrials.gov registry record · Phase 3
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
A Phase 3 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,478
- Enrollment target
NCT05610280 is a Phase 3 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 1,478 participants.
The verdict
NCT05610280, a Phase 3 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,478 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.
Interventions
- DRUG Placebo
- DRUG Olezarsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,478 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05610280
The ClinicalTrials.gov registry entry for NCT05610280 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,478 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05610280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05610280 about?
NCT05610280 is a clinical study titled "A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia". The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.
What is the current status of trial NCT05610280?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,478 participants. The study started on 2022-11-21. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT05610280?
The interventions under investigation include: Placebo (DRUG), Olezarsen (DRUG).
Who is sponsoring clinical trial NCT05610280?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.